NLS Pharmaceutics Amends Merger Agreement with Kadimastem

Ticker: NCEL · Form: 6-K · Filed: May 5, 2025 · CIK: 1783036

Nls Pharmaceutics LTD. 6-K Filing Summary
FieldDetail
CompanyNls Pharmaceutics LTD. (NCEL)
Form Type6-K
Filed DateMay 5, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: merger, amendment, legal-agreement

TL;DR

NLS Pharma just tweaked its merger deal with Kadimastem AGAIN. Third amendment filed May 5, 2025.

AI Summary

On May 5, 2025, NLS Pharmaceutics Ltd. entered into a third amendment to its Merger Agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This amendment modifies the terms of the original agreement, which was first established on November 4, 2024, and previously amended on January 30 and February 17, 2025.

Why It Matters

This filing indicates ongoing adjustments to a significant merger, which could impact the future structure and operations of NLS Pharmaceutics and Kadimastem.

Risk Assessment

Risk Level: medium — Amendments to merger agreements can signal complexities or renegotiations that may affect the deal's completion or terms.

Key Players & Entities

FAQ

What is the primary purpose of the Third Amendment to the Merger Agreement?

The filing states that the Third Amendment modifies the terms of the Agreement and Plan of Merger between NLS Pharmaceutics Ltd., Kadimastem Ltd., and NLS Pharmaceutics (Israel) Ltd.

When was the original Merger Agreement entered into?

The original Agreement and Plan of Merger was entered into on November 4, 2024.

What were the previous amendment dates for the Merger Agreement?

The Merger Agreement was previously amended on January 30, 2025, and on February 17, 2025.

Which entities are parties to the Merger Agreement?

The parties to the Merger Agreement are NLS Pharmaceutics Ltd., Kadimastem Ltd., and NLS Pharmaceutics (Israel) Ltd.

What is the filing date of this Form 6-K?

This Form 6-K was filed on May 5, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 5, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing